Noxxon reveals results from PHASE 1/2 trial of NOX-A12/KEYTRUDA®
Category: #health  By Mateen Dalal  Date: 2019-10-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Noxxon reveals results from PHASE 1/2 trial of NOX-A12/KEYTRUDA®

Colorectal cancer (CRC), also known as bowel or colon cancer, is a type of cancer that involves abnormal growth of cells that can invade or spread to other parts of the body. Growing prevalence of CRC has led various pharmaceuticals firms to develop novel drugs using advanced research and clinical trials.

NOXXON Pharma N.V. is one such firm that develops innovative cancer treatments and has recently announced new clinical findings from the Phase 1/2 trial of NOX-A12 paired with Keytruda® (pembrolizumab) in patients suffering from microsatellite-stable, metastatic colorectal and pancreatic cancer.

Reportedly, the data was presented at the ESMO (European Society for Medical Oncology) Congress 2019, held in Spain.

According to reliable sources, the combination of pembrolizumab and NOX-A12 showed stable disease in 25% of patients, induced an immune response and sustained time on treatment, compared to previous therapy for 35% of patients. Moreover, constant follow-up of patients has established an overall survival statistic of 22% at 12 months and 42% at 6 months.

Speaking on the development, Aram Mangasarian, CEO, NOXXON, said that both metastatic pancreatic and colorectal cancers have a very limited remedial alternative. However, the positive results from the clinical data and the fact that three heavily pre-treated patients lived over a year reinforces the capability of NOX-A12 to target the tumor microenvironment.

Incidentally, in addition to the positive outcomes, the company has also prior achieved a monumental landmark when it completed the capital increase of €1 million which was previously halted. Noxxon has also revealed that its future investments are fixed for the upcoming investment round.

Commenting on the attained capital, Mangasarian said that the company is delighted to reveal the conclusion of the capital increase which has positioned itself at a secure position which would ensure the progression and beginning of Phase 1/2 clinical study in brain cancer.

Noxxon is also dedicated towards building the clinical studies sites in Germany where the trial was given a green signal by the Ethics Committees and regulatory authorities, he added.

Source Credit: https://www.noxxon.com/downloads/pressrel/2019-09-29_ESMO_Poster_PR_EN.pdf

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...